pembrolizumab,axitinib,nivolumab,ipilimumab
merck,bms,pfizer
['kn42', 'cm214', 'kn426', 'rcc,(-irccs),(-srcc),(-urcc)', ' ipi ']
#mrcc in 1l pick any tx with os benefit, but
cm214:use ipi upfront, maybe efficacy with tki in 2l, qol, long term efficacy benefit kn426:more specific vegf-tki in frontline and maybe efficacy of multitki in 2l, half-life making easier the management of ae #esmo2022
Scientific Committee Member LACOG - GU. Medical Oncologist at Hospital Albert Einstein and CPO. Owner and founder BIO. Following or RT does not mean endorsement